November 19, 2010Antiviral chemistry & chemotherapy

Therapeutic Targeting of HCV Internal Ribosomal Entry Site RNA

View Full Paper

Ask AI

Bookmark

Population

HCV IRES RNA models (in vitro and cell culture)

Design

Review

Authors

DDDarrell R. DavisUniversity of Utah PSPunit P. SethAlnylam Pharmaceuticals (United States)

Discussion

Member takes

Implication

Offers benzimidazole scaffolds for HCV discovery; leaves open in vivo efficacy and clinical translation.

Structured PICO

Population

HCV IRES RNA models (in vitro and cell culture)

Intervention

Oligonucleotide therapeutics and small molecule inhibitors (e.g., benzimidazole scaffold) targeting the HCV internal ribosomal entry site (IRES)

Outcome

Inhibition of IRES function and viral replicationsurrogate

Small molecule inhibitors targeting the HCV IRES induce large RNA conformational changes, providing a framework for structure-based drug design of novel HCV therapeutics.

Limitations

stability and drug delivery challenges for oligonucleotide therapeutics

Cite This Study

Davis et al. (2010) studied this question.

synapsesocial.com/papers/6a710e09e71d69abee090348 https://doi.org/10.3851/imp1693

View Full Paper

Ask AI

Bookmark

Therapeutic Targeting of HCV Internal Ribosomal Entry Site RNA

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Therapeutic Targeting of HCV Internal Ribosomal Entry Site RNA

Discussion

Member takes

Implication

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider